Core Viewpoint - BioNTech SE has received overwhelming approval from CureVac shareholders for its exchange offer, with over 99.16% voting in favor, and expects to complete the offer promptly [1][9]. Group 1: Offer Details - The exchange offer for CureVac shares is set to expire at 9:00 a.m. Eastern Time on December 3, 2025, with shareholders advised to tender their shares by 6:00 p.m. Eastern Time on December 2, 2025 [2][9]. - The exchange ratio is established at 0.05363 of a BioNTech American Depositary Share (ADS) for each CureVac share, based on a volume-weighted average price of $101.88 over the 10 trading days ending November 25, 2025 [3][9]. - BioNTech will recalculate the exchange ratio if the offer is extended and will announce the new ratio via press release [3]. Group 2: Tendering Process - CureVac shareholders holding shares through brokers should provide instructions to their brokers to tender shares, while other shareholders can follow the instructions in the Letter of Transmittal [4]. - Following the acceptance of tendered shares, BioNTech will initiate a subsequent offering period of not less than 10 business days [4]. Group 3: Conditions and Reorganization - The offer is contingent upon BioNTech acquiring at least 80% of the outstanding CureVac shares, with a potential reduction to 75% if certain conditions are met [5]. - Upon satisfaction of all conditions, non-tendering CureVac shareholders will receive BioNTech ADSs or cash in lieu of fractional ADSs, subject to a 15% Dutch dividend withholding tax [6]. Group 4: Regulatory and Market Context - The announcement of the exchange ratio serves as a pricing notice under EU regulations for the public offering of BioNTech ADSs to CureVac shareholders in several European countries [7][9]. - BioNTech is a biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases, leveraging its expertise in mRNA technology [10].

Core Insights - BioNTech will host an Innovation Series R&D Day on November 11, 2025, to discuss its strategy and clinical progress [1] - The event will be accessible online, with a replay available for one year [2] Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [3] - The company utilizes a variety of computational discovery and therapeutic modalities for rapid biopharmaceutical development [3] - BioNTech's oncology portfolio includes mRNA cancer immunotherapies, immunomodulators, targeted therapies like antibody-drug conjugates (ADCs), and CAR T cell therapies [3] - The company is also developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [3] - BioNTech collaborates with several global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Roche [3]

Core Viewpoint - BioNTech SE will announce its financial results for Q3 2025 on November 3, 2025, and will host a conference call and webcast for discussion [1] Group 1: Financial Results Announcement - The financial results for the third quarter of 2025 will be disclosed on November 3, 2025 [1] - A conference call and webcast will take place at 8:00 a.m. EST (2:00 p.m. CET) on the same day for investors and analysts [1] Group 2: Accessing the Conference Call - Participants can register for the live conference call via a provided link, with dial-in numbers and a PIN sent post-registration [2] - It is recommended to register at least one day in advance [2] - The slide presentation and audio of the webcast will be accessible through a specified link [2] Group 3: Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [4] - The company utilizes a variety of computational discovery and therapeutic modalities for rapid biopharmaceutical development [4] - BioNTech's oncology product candidates include mRNA cancer immunotherapies, immunomodulators, and targeted therapies like antibody-drug conjugates and CAR T cell therapies [4] - The company is also developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [4] - BioNTech has established collaborations with various global pharmaceutical companies, including Pfizer and Bristol Myers Squibb [4]

Core Insights - BioNTech SE, in collaboration with InstaDeep Ltd., will host its second AI Day on October 1, 2025, in London, focusing on BioNTech's AI strategy and its applications in the company's pipeline and internal processes [1] Company Overview - BioNTech is a global biopharmaceutical company specializing in next-generation immunotherapy, developing innovative therapies for cancer and serious diseases [3] - The company utilizes a variety of computational discovery and therapeutic modalities to rapidly develop novel biopharmaceuticals [3] - BioNTech's oncology product candidates include mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and CAR T cell therapies [3] - The company is also researching multiple mRNA vaccine candidates for infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities [3] - BioNTech has established partnerships with several global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Roche Group [3]

Core Viewpoint - BioNTech SE will announce its financial results for the second quarter of 2025 on August 4, 2025, and will host a conference call and webcast for stakeholders to discuss these results and provide a corporate update [1]. Group 1: Financial Results Announcement - The financial results for Q2 2025 will be disclosed on August 4, 2025 [1]. - A conference call and webcast will take place at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day [1]. Group 2: Accessing the Conference Call - Participants can register for the live conference call via a provided link, with dial-in numbers and a PIN sent post-registration [2]. - It is recommended to register at least one day in advance for the call [2]. - The slide presentation and audio of the webcast will be accessible through a specified link [2]. Group 3: Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [4]. - The company utilizes a variety of computational discovery and therapeutic modalities for rapid biopharmaceutical development [4]. - BioNTech's oncology product candidates include mRNA cancer immunotherapies, immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies [4]. - The company is also developing multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [4]. - BioNTech has established collaborations with various global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Genentech [4].

Core Points - BioNTech SE announced the resignation of Ryan Richardson as Chief Strategy Officer effective September 30, 2025, to pursue new professional opportunities [1] - Richardson joined BioNTech in 2018 and has been instrumental in raising over USD 1 billion through various financing activities, including the Initial Public Offering on Nasdaq [2] - His contributions include building Global Strategy and Corporate Development functions, enhancing Capital Markets and Investor Relations, and serving on the Board of Directors of InstaDeep Ltd. since its acquisition in 2023 [2] Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases [4] - The company has a diversified oncology product portfolio, including mRNA cancer immunotherapies, immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies [4] - BioNTech collaborates with various global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Genentech, to advance its research and development efforts [4]

Core Points - BioNTech SE will announce its financial results for Q1 2025 on May 5, 2025, and will host a conference call and webcast at 8:00 a.m. EDT [1] - The conference call will be accessible via telephone registration, and participants are encouraged to register at least one day in advance [2] - A replay of the webcast will be available shortly after the call and archived for 30 days on the company's website [3] Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and serious diseases [4] - The company utilizes a variety of computational discovery and therapeutic drug platforms for rapid biopharmaceutical development [4] - BioNTech's oncology product candidates include mRNA cancer immunotherapies, immunomodulators, targeted therapies like antibody-drug conjugates (ADCs), and CAR T cell therapies [4] - The company is also developing multiple mRNA vaccine candidates for infectious diseases, leveraging its expertise in mRNA development and manufacturing [4] - BioNTech has established collaborations with various global pharmaceutical companies, including Pfizer, Genentech, and Regeneron [4]